Combined serum mesothelin and carcinoembryonic antigen measurement in the diagnosis of malignant mesothelioma

30/03/2016
Author:  Kazuya Fukuoka; Kozo Kuribayashi; Shusai Yamada; Kunihiro Tamura; Chiharu Tabata and Takashi Najano

Kazuya Fukuoka, Kozo Kuribayashi, Shusai Yamada, Kunihiro Tamura, Chiharu Tabata and Takashi Najano
Molecular and Clinical Oncology 1: 942-948, 2013

Malignant mesothelioma (MM) is a highly aggressive tumor associated with asbestos exposure. The iden­tification of a marker specific for MM may be of considerable value for the early detection of this tumor and may be used in particular to screen groups with a history of asbestos exposure. The aim of this study was to evaluate serum soluble meso­thelin‑related peptide (SMRP) levels as a diagnostic marker for MM and investigate whether its diagnostic value is enhanced by combination with other biomarkers. Serum SMRP levels were measured using a quantitative enzyme‑linked immuno­sorbent assay in 96 patients with MM, 55 patients with lung cancer and 39 individuals with a history of asbestos exposure. Receiver operating characteristic curves were constructed for performance evaluation. Stepwise logistic regression analysis was used to select marker combinations (MCs). Serum SMRP levels in patients with MM were significantly higher compared to those in the other groups (P<0.001). The sensitivity of SMRP levels in diagnosing MM was 56% and its specificity for MM vs. lung cancer and individuals with asbestos expo­sure was 87 and 92%, respectively. The area under the curve (AUC) was 0.76 [95% confidence interval (CI): 0.68‑0.83] for the differentiation between MM and lung cancer and 0.78 (95% CI: 0.71‑0.86) for the differentiation between MM and individuals with asbestos exposure. For the MC of presence of effusion, SMRP and carcinoembryonic antigen (CEA) levels, the AUC for the differentiation between MM and lung cancer (0.92; 95% CI: 0.88‑0.97) and the differentiation between MM and individuals with asbestos exposure (0.93; 95% CI: 0.87‑1.0) was significantly higher compared to that for SMRP alone (P=0.0001 and 0.0058, respectively). While the specificity of this MC was comparable to SMRP alone, its sensitivity was ~20% higher compared to that of SMRP alone. Therefore, combining SMRP and CEA improves the diag­nostic performance of SMRP alone. A combination of serum biomarkers, including SMRP, may facilitate the non‑invasive diagnosis of MM.

CLOSE

You can change the country filter for contents in our website. You will then see local contact information and other information available for that country. Please choose your country in the list below:

Please log in to react

Welcome to Fujirebio

It looks as if you are visiting from the United States. The content of this website is not destined for United States visitors.

If you continue your visit you confirm that you understand that not all of the products you will see listed are FDA cleared. FDA cleared products may not be cleared for all indications mentioned on this site. Product claims may differ from country to country based on regulations and approvals.

Please contact your country representative for further details.